Article
Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2020
Sztupinszki Zsofia, Diossy Miklos, Krzystanek Marcin, Borcsok Judit, Pomerantz Mark M, Tisza Viktoria, Spisak Sandor, Rusz Orsolya, Csabai István, Freedman Matthew L, Szallasi Zoltan
Abstract excerpt
PURPOSE: Prostate cancers with mutations in genes involved in homologous recombination (HR), most commonly BRCA2, respond favorably to PARP inhibition and platinum-based chemotherapy. We investigated whether other prostate tumors that do not harbor deleterious mutations in these particular genes can similarly be deficient in HR, likely rendering those sensitive to HR-directed therapies. EXPERIMENTAL DESIGN:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.